Vitamin D3 regulation of transforming growth factor- system in epithelial and fibroblastic cells-relationships to plasminogen activation

Journal of Investigative Dermatology Symposium Proceedings

Volumn 1, Issue 1, 1996, Pages 33-38

  Koli, Katri ^a,b   Kcski Oja, Jorma ^b  

^a Departments of Virology   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Fibroblasts; Tgf , epithelial cells; Vitamin d3

Indexed keywords

CARRIER PROTEIN; COLECALCIFEROL; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN; PLASMINOGEN ACTIVATOR; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; CELL CULTURE; CELL DIVISION; DRUG EFFECT; EPITHELIUM CELL; FIBROBLAST; KERATINOCYTE; METABOLISM; MOUSE; RABBIT;

ANIMALS; CARRIER PROTEINS; CELL DIVISION; CELLS, CULTURED; CHOLECALCIFEROL; EPITHELIAL CELLS; FIBROBLASTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KERATINOCYTES; LATENT TGF-BETA BINDING PROTEINS; MICE; PLASMINOGEN ACTIVATORS; RABBITS; TRANSFORMING GROWTH FACTOR BETA;

EID: 0030112309     PISSN: 10870024     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Dcrynck R, Dickson RB: Evidence that transforming growth factor- is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48:417428, 1987
2. Colletta AA, Wakefield LM, Howell FV, van Roozendal KEP. Danielpour D, Ebbs SR, Sporn MB, Baum M: Antiestrogens induce the secretion of active TGF-β from human fetal fibroblasts. BrJ Cancer 62:405-409, 1990
3. Arteaga CL, Coffey RJ Jr, Dugger TC, McCutchcn CM, Moses HL, Lyons RM: Growth stimulation of human breast cancer cells with anti-transforming growth factor- antibodies: evidence for negative autocrine regulation by transforming growth factor-/3. Cell Cramh Differ 1:367-374, 1990
4. Click AB, Flanders KC, Danielpour D, Yuspa SH, Sporn MB: Retinoic acid induces transforming growth factor-/}2 in cultured keratinocytes and mouse epidermis. CM Regul 1:87-97, 1989
5. Benz DJ, Haussler MR, Thomas MA, Speelman B, Komm BS: High-affinity androgen binding and androgenic regulation of O!|(I)-procollagen and transforming growth factor-/} steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells. Endocrinology 128:2723-2730, 1991
6. Colletta AA, Wakefield LM, Howell FV, Danielpour D, Baum M, Sporn MB: The growth-inhibition of human breast cancer pells by a novel synthetic progestin involves the induction of transforming growth factor-/}._/ Clin Invest 87:277-283, 1991
7. Millan FA, Denhez F, Kodaiah P, Akhurst RJ: Embryonic gene expression patterns of TGF-βl, -β2, and -/}3 suggest different developmental functions in vivo. Development 111:131-144, 1991
8. Bascom CC, Wolfshohl JR, Coffey RJ Jr, Madisen L, Wcbb NR, Purchio AR, Derynck R, Moses HL: Complex regulation of transforming growth factor-β1 , β2, and -)33 mRNA expression in mouse fibroblasts and keratinocj-tes by transforming growth factor-/}! and -β2. Mol Cell Biol 9:5508-5515, 1989
9. Roberts AB, Sporn MB: Mechanistic interrelationship between two superfamilies: the steroid/thyroid receptors and transforming growth factor-/}. Cancer Snrv 14:205-220, 1992
10. Olofsson A, Miyazono K, Kanzaki T, Colosetti P, Engström U, Heldin C-H: Transforming growth factor-/31, -/32, and -/33 secreted by a human glioblastoma cell line: identification of small and ditferent forms of large latent complexes. J Biol Chcm 267:19482-19488, 1992
11. Brown PD, Wakefield LM, Levinson AD, Sporn MB: Physiochemical activation of recombinant latent transforming growth factor-/i's 1, 2, and 3. Growth Factors 3:35-43, 1990
12. Lyons RM, Keski-Oja J, Moses HL: Proteolytic activation of latent transforming growth factor-/? from fibroblast conditioned medium. J Cell Biol 106:15971605, 1988
13. Lyons RM, Gentry L, Purcliio AF, Moses HL: Mechanisms of activation of latent recombinant transforming growth factor-/} by plasmin.J Cell Biol 110:13611367, 1990
14. Kojima S, Rifkin DB: Mechanism of retinoid-induced activation of latent transforming growth factor-/} in bovine endothclial cells. J Cell Physiol 155:323-332, 1993
15. Laiho M. Saksela O, Keski-Oja J: Transforming growth factor-/} alters plasminogen activator activity in human skin fibroblasts. Exp Cell Res 164:399-407, 1986
16. Laiho M, Keski-Oja J: Growth factors in the regulation of pericellular proteolysis: a review. Cancer Res 49:2533-2553, 1989
17. Haussler MR, McCain TA: Basic and clinical concepts related to vitamin D metabolism and activation. N.EnglJ MeJ 297:974-983, 1977
18. Norman AW, Nemere I. Zhou L-X, Bishop JE, Löwe KE, Maiyar AC, Collins ED, Taoka T, Segreev I, Farach-Carson MC: l,25(OH)2-vitamin D3, a steroid that produces biological effects via both genomic and nongenomic pathways. J Steroid Biochem Mol Biol 41:231-240, 1992
19. de Boland AR, Nemere I: Rapid actions of vitamin D compounds. J Cell Biochem 49:32-36, 1992
20. Bilde DD: Clinical counterpoint: vitamin D: new actions, new analogs, new therapeutic potential. Endocr Rev 13:765-784, 1992
21. Koli K, Keski-Oja J: Vitamin D3 and calcipotriol enhance the secretion of transforming growth factor-/}! and -/}2 in cultured murine keratinocytes. Grouth Factors 8:153-163, 1993
22. Koli K, Keski-Oja J: 1,25-dihydroxyvitamin D3 enhances the expression of transforming growth factor-/}! and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-1546, 1995
23. Laiho M, DeCaprio JA, Ludlow JW, Livingstone DM, Massagué J: Growth inhibition by TGF-/3 linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175-185, 1990
24. Taipale J, Koli K, Keski-Oja J: Release of pericellular matrix-associated trans-forming growth factor-/31 of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Client 267:25378-25388, 1992
25. Taipale J, Matikainen S, Hurme M, Keski-Oja J: Induction of transforming growth factor-l and its receptor during myeloid leukemia cell differentiation. Cell Gmnh Differ 5:1309-1319, 1994
26. Hedman K, Kurkinen M, Alitalo A, Vaheri A, Johnsson S, Hôôk M: Isolation of pericellular matrix of human fibroblast cultures. J Cell Biol 81:83-91, 1979
27. Granelli-Pipemo A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 146:223-282, 1981
28. Stoppelli MP, Tacchctti C, Cubellis MV, Cordi A, Hearing VJ, Cassani G, Apelli E, Blasi F: Automne saturation of pro-urokinase receptor on human A431 cells. Cell 45:675-684, 1986
29. Koli K, Keski-Oja J: Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J Invest Dennatol 101:706712, 1993
30. Grondahl-Hansen J, Ralfkiaer E, Nielsen LS, Kristenscn P. Frentz G, Dano K: Immunohistochemical localization of urokinase-type and tissue-type plasminogen activators in psoriatic skin. J Invest Dcrtnatol 88:28-32, 1987
31. Yu VC, Delsert C, Andersen D, HollowayJM, Devary OV, Näär AM, Kim SY, Boutin J-M, Glass CK, Rosenfeld MG: RXR: A coregulator that enhances binding of rctinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell 67:1251-1266, 1991
32. MacDonald PN, Dowd DR, Nakajima S, Galligan MA, Reeder MC, Haussler CA. Ozato K, Haussler MR: Retinoid X receptors stimulate and 9-fis retinoic acid inhibits 1,25-dihydroxyvitamin Deactivated expression of the rat osteocalcin gene. Mol Cell Biol 13:5907-5917, 1993
33. Click AB, Kulkanii AB, Tennenbaum T, Hennings H, Flanders KC, O'Reilly M, Sporn MB, Karlsson MB, Yuspa SH: Loss of expression of transforming growth factor- in skin tumors is associated with hyperproliferation and high risk for malignant conversion. I'roc Nail Acad Sei U S A 90:6076-6080, 1993
34. Kulkarni AB, Huh C-G, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S: Transforming growth factor-/31 null mutation in mice causes excessive inflammation response and early death. PTOC Nail Acad Sei U S A 90:770-774, 1993
35. Sellheyer K, BickenbachJB, Rothnagel JA, Bundman D, Longley MA, Krieg T, Roche NS, Roberts AB, Roop DR: Inhibition of skin development by overexpression of transforming growth factor-l in the epidermis of transgcnic mice. Proc Kau Acad Sei USA 90:5237-5241, 1993
36. Flaumenhaft R, Abe M, Sato Y, Miyazono K, HarpelJ, Helsin C-H, Rifkin DB: Role of the latent TGF-/3 binding protein in the activation of latent TGF-/3 by co-cultures of endothelial and smooth muscle cells._/ Cell Biol 120:995-1002, 1993
37. Fynan TM, Reiss M: Resistance to inhibition of cell growth by transforming growth factor- and its role in oncogcnesis. Crit Rev Oncogen 4:493-540, 1993
38. Kimchi A, Wang X-F, Weinberg RA, Cheifetz S, Massagué J: Absence of TGF-/3 receptors and growth-inhibitor)' response in retinoblastoma cells. Science 240:196-198. 1988
39. Samuel SK, Hurta RAR, Kodaiah P, Khalil N, Turley EA, Wright JA, Greenberg AH: Automne induction of tumor protease production and invasion by metallothiotein-regulated TGF-J31 (Ser223, 225). EMBO J 11:1599-1605, 1992
40. Keski-Oja J, Blasi F, Leof EB, Moses HL: Regulation of the synthesis and activity of urokinase plasminogen activator in A549 human lung carcinoma cells by transforming growth factor-. J Cell Blot 106:451-459, 1988
41. Dickens T-A, Colletta AA: The pharmacological manipulation of members of the transforming growth factor- family in the chemoprevention of breast cancer. BioEssajs 15:71-74, 1993
42. Dano K, Andreasen P, Grondahl-Hansen J, Kristensen K, Nielsen L, Skriver L: Plasminogen activators, tissue degradation and cancer. Aiv Cancer Res 44:139266, 1985